Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Feb 12:15:1309993.
doi: 10.3389/fendo.2024.1309993. eCollection 2024.

Effects of different gonadotropin preparations in GnRH antagonist protocol for patients with polycystic ovary syndrome during IVF/ICSI: a retrospective cohort study

Zhengyan Hu #  1   2   3 , Rujun Zeng #  1   2 , Rui Gao  1   2 , Mingli Chen  4   5 , Xiumei Liu  4   5 , Qiong Zhang  4   5 , Lang Qin  1   2 , Xun Zeng  1   2
Affiliations

Effects of different gonadotropin preparations in GnRH antagonist protocol for patients with polycystic ovary syndrome during IVF/ICSI: a retrospective cohort study

Zhengyan Hu et al. Front Endocrinol (Lausanne). .

Abstract

Purpose: To compare the effects of recombinant FSH alfa (rFSH-alfa), rFSH-beta, highly purified human menopausal gonadotropin (HP-hMG) and urinary FSH (uFSH) in women with polycystic ovarian syndrome who have undertaken the GnRH antagonist protocol during IVF/ICSI treatment.

Method: A single-center retrospective cohort study including women with PCOS who received the GnRH antagonist protocol from January 2019 to July 2022 was conducted. Patients were divided into rFSH-alfa group, HP-hMG group, uFSH group, and rFSH-beta group, and the number of oocytes retrieved, clinical pregnancy rate of the fresh cycle (primary outcomes), embryo quality, and severe OHSS rate (secondary outcomes) were compared.

Results: No statistical differences were found among the four groups in fresh cycle clinical pregnancy rate (p=0.426), nor in the subgroup analyses. The HP-hMG group had a smaller number of oocytes retrieved and a higher high-quality D3 embryo rate than the three FSH groups (p<0.05). No statistical differences were found among the four groups in the severe OHSS rate (p=0.083).

Conclusion: For women with PCOS undergoing the GnRH antagonist protocol, the clinical pregnancy rates of fresh IVF/ICSI-ET cycle are similar for all four types of Gn. With a lower risk of OHSS and a similar number of high-quality and available embryos, HP-hMG may have an advantage in the PCOS population.

Keywords: GnRH antagonist protocol; ICSI; IVF; gonadotropin; polycystic ovary syndrome.

PubMed Disclaimer

Conflict of interest statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

References

    1. McCartney CR, Marshall JC. CLINICAL PRACTICE. Polycystic ovary syndrome. N Engl J Med (2016) 375(1):54–64. doi: 10.1056/NEJMcp1514916 - DOI - PMC - PubMed
    1. Costello MF, Misso ML, Balen A, Boyle J, Devoto L, Garad RM, et al. . Evidence summaries and recommendations from the international evidence-based guideline for the assessment and management of polycystic ovary syndrome: assessment and treatment of infertility. Hum Reprod Open (2019) 2019(1):hoy021. doi: 10.1093/hropen/hoy021 - DOI - PMC - PubMed
    1. Broer SL, Dólleman M, Opmeer BC, Fauser BC, Mol BW, Broekmans FJM. AMH and AFC as predictors of excessive response in controlled ovarian hyperstimulation: a meta-analysis. Hum Reprod Update (2011) 17(1):46–54. doi: 10.1093/humupd/dmq034 - DOI - PubMed
    1. La Marca A, Sunkara SK. Individualization of controlled ovarian stimulation in IVF using ovarian reserve markers: from theory to practice. Hum Reprod Update (2014) 20(1):124–40. doi: 10.1093/humupd/dmt037 - DOI - PubMed
    1. Lambalk CB, Banga FR, Huirne JA, Toftager M, Pinborg A, Homburg R, et al. . GnRH antagonist versus long agonist protocols in IVF: a systematic review and meta-analysis accounting for patient type. Hum Reprod Update (2017) 23(5):560–79. doi: 10.1093/humupd/dmx017 - DOI - PubMed

MeSH terms

Substances